LKB1 mutation status is associated with intrinsic resistance to immunotherapy checkpoint blockade (ICB) in KRAS-mutant non-small cell lung cancer (NSCLC) (Koyama et al., 2016; Skoulidis et al., 2018). Here, KRAS is linked to non-small cell lung carcinoma.